Cardiac dysfunction in the trastuzumab clinical trials experience (2002)

Peer-Reviewed Study · Tier 1 — Primary Document · Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D · March 1, 2002

Seidman A et al., 2002-03-01: Retrospective review of cardiac dysfunction across seven phase II/III trastuzumab trials. Incidence was 27% with trastuzumab plus anthracycline/cyclophosphamide, 13% with paclitaxel plus trastuzumab, 3-7% with trastuzumab alone, and 79% of affected patients improved on heart-failure treatment.

The incidence was greatest in patients receiving concomitant trastuzumab and anthracycline plus cyclophosphamide (27%).

Abstract (Results)

Seidman A et al., 2002-03-01: Retrospective review of cardiac dysfunction across seven phase II/III trastuzumab trials. Incidence was 27% with trastuzumab plus anthracycline/cyclophosphamide, 13% with paclitaxel plus trastuzumab, 3-7% with trastuzumab alone, and 79% of affected patients improved on heart-failure treatment. Maker: trastuzumab is Genentech/Roche (Herceptin); the trials were sponsored by the manufacturer and several authors were Genentech employees (Shak, Paton, Ashby per the author list/affiliations in the record). Comparator: anthracycline+cyclophosphamide alone (8%) and paclitaxel alone (1%). The book's 'up to 28 percent' is very close to this paper's 27%; the same paper's 79% improvement rate is the counterweight on reversibility.